Ocuphire Pharma Announces Results from Two Phase 2 Clinical Studies of Nyxol® Eye Drops

FARMINGTON HILLS, Mich.--(BUSINESS WIRE)--Ocuphire Pharma, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, announced statistically significant and clinically meaningful results from its recently completed two Phase 2b studies of its lead drug candidate, Nyxol Eye Drops. Top-line results of the primary and secondary endpoints of the MIRA-1 and ORION-1 studies provided confirmator

Full Story →